Pipeline

Robust drug pipeline: Scandion Oncology’s leading product SCO-101 is expected to be used in combination with drugs like topoisomerase 1 inhibitors, taxanes and antiestrogens. In addition to SCO-101, the company is also developing SCO-201 and SCO-301, which is expected to be used as add on to other anti-cancer drugs in the treatment of drug resistant cancer diseases. Scandion Oncology expects its present drug pipeline to cover more than 50% of all anti-cancer drugs used today.


 

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union